The Effectiveness and Safety of First-Line Thioguanine in Thiopurine-Naïve Inflammatory Bowel Disease Patients.
Inflamm Bowel Dis
; 2023 Sep 02.
Article
en En
| MEDLINE
| ID: mdl-37658804
After 12 months, first-line thioguanine therapy was still used by 86% of thiopurine-naïve patients with inflammatory bowel disease and clinically effective in 53%. The safety profile was acceptable and only 8% of patients ceased therapy due to adverse events.
Texto completo:
1
Banco de datos:
MEDLINE
Tipo de estudio:
Observational_studies
Idioma:
En
Año:
2023
Tipo del documento:
Article